Related Experiment Videos
The effect of Antineoplaston, a new antitumor agent on malignant brain tumors
1Department of Neurosurgery, Kurume University School of Medicine, Japan.
Abstract:
Antineoplaston (Ap), a new antitumor agent, was clinically tested for effects on malignant brain tumors. The materials were 3 cases of glioblastoma (G,B), 2 cases of anaplastic astrocytoma, 1 case of pontine glioma, 2 cases of metastatic brain tumor and 1 case of medulloblastoma. All patients underwent radiochemotherapy and surgical resection of the tumors except the cases of pontine glioma, metastatic brain tumor and anaplastic astrocytoma. For gliomas, radiochemotherapy was used with Hu-IFN-beta. Ap was administered at a dose of 7-10 g/day in combination with remission maintenance therapy of gliomas. Complete response was obtained in one anaplastic astrocytoma. Partial response was obtained in 2 cases, a pontine glioma and a metastatic brain tumor. No change was observed in 2 cases, an anaplastic astrocytoma and a multiple brain metastasis. Progression of the disease was observed in 4 cases, 3 glioblastomas and 1 medulloblastoma, which showed continuous increase in tumor size. The effects of Ap on malignant brain tumors were considered due to synergy, since it was administered with other drugs and acceleration of tumor cellular differentiation. Ap is useful as an approach to remission maintenance therapy for brain tumors.
Insights
Antineoplaston (Ap) showed varied effects on malignant brain tumors, with one complete response in anaplastic astrocytoma and partial responses in other brain tumors. Further research is needed to optimize its use in cancer treatment.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Malignant brain tumors present significant treatment challenges.
- Antineoplaston (Ap) is an investigational antitumor agent.
- Clinical evaluation of Ap in brain tumor patients is warranted.
Purpose of the Study:
- To assess the clinical efficacy of Antineoplaston (Ap) in patients with malignant brain tumors.
- To evaluate the safety and response rates of Ap in combination with standard therapies.
Main Methods:
- A cohort of 10 patients with various malignant brain tumors (glioblastoma, anaplastic astrocytoma, pontine glioma, metastatic brain tumor, medulloblastoma) was treated.
- Patients received Antineoplaston (Ap) at 7-10 g/day, often in conjunction with radiochemotherapy, surgery, and Hu-IFN-beta.
- Treatment protocols varied based on tumor type and prior interventions.
Main Results:
- One complete response was observed in anaplastic astrocytoma.
- Partial responses were noted in one pontine glioma and one metastatic brain tumor.
- Stable disease occurred in one anaplastic astrocytoma and one case of multiple brain metastases.
- Disease progression was observed in three glioblastomas and one medulloblastoma.
Conclusions:
- Antineoplaston (Ap) demonstrated a range of responses in malignant brain tumors, suggesting potential utility.
- The observed effects may be attributed to synergistic interactions with other therapies and promotion of tumor cell differentiation.
- Ap shows promise as an adjunct for remission maintenance therapy in brain tumors.